Booth 485
Stockholm, Sweden
Introducing ReciBioPharm, Recipharm's biologics business combining the capabilities of recently acquired CDMOs Arranta Bio, GenIbet and Vibalogics. Our expanded biologics drug development and manufacturing services encompass technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, recombinant proteins, nucleic acid-based mRNA and plasmid DNA production.

Established in 1995, Recipharm’s manufacturing, fill-finish, and delivery-device services canvass a wide variety of drug dosage forms and modalities. Recipharm is an industry leading CDMO with over 30 facilities and 9,000 employees globally – servicing companies that are developing small-molecules, biologics, and drug-device combinations.